Effects of eplerenone on markers of myocardial fibrosis, 6-minute walk distance, and quality of life in adults with tetralogy of fallot and complete transposition of the great arteries

Sandeep S. Sodhi, Tony J. Zhang, Rachel McDonald, Vanessa Al Rashida, Nitin Kondapalli, Philip Barger, Philip Ludbrook, Ari M. Cedars

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Ventricular dysfunction is common among patients with repaired cyanotic congenital heart disease. To date, no pharmacologic intervention has been demonstrated to be beneficial in this setting. To begin addressing this knowledge gap, we conducted a single-center prospective, randomized, open-label pilot study to investigate the effects of eplerenone on serologic markers of collagen turnover and inflammation, 6-minute walk distance, and quality of life in patients with tetralogy of Fallot (TOF) or transposition of the great arteries with a systemic right ventricle (transposition of the great arteries [TGA]). Patients were randomized to a 3-month drug-free period at the beginning of the treatment period or at the end. All patients received 12 months of eplerenone therapy during the treatment period. Twenty-six patients were enrolled in the trial; 17 completed the study protocol: 8 with TOF and 9 with TGV. Eplerenone had no effect on serum levels of procollagen 1 N-terminal peptide (PINP), procollagen 3 N-terminal peptide (PIIINP), or galectin-3 (G3). Similarly, eplerenone had no effect on 6-minute walk distance or quality of life. In conclusion, PINP and PIIINP levels are as high as or higher in patients with TOF and TGA than in patients with normal cardiac anatomy and heart failure, whereas G3 levels are lower. Eplerenone is well tolerated by adults born with congenital heart disease.

Original languageEnglish (US)
Pages (from-to)12-19
Number of pages8
JournalBaylor University Medical Center Proceedings
Volume31
Issue number1
DOIs
StatePublished - Jan 1 2018
Externally publishedYes

Fingerprint

Transposition of Great Vessels
Tetralogy of Fallot
Fibrosis
Quality of Life
Galectin 3
Procollagen
Heart Diseases
Heart Failure
Ventricular Dysfunction
eplerenone
Heart Ventricles
Anatomy
Collagen
Therapeutics
Inflammation
Peptides
Serum
Pharmaceutical Preparations

Keywords

  • Adult congenital heart disease
  • Eplerenone
  • Tetralogy of Fallot
  • Transposition of the great vessels

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Effects of eplerenone on markers of myocardial fibrosis, 6-minute walk distance, and quality of life in adults with tetralogy of fallot and complete transposition of the great arteries. / Sodhi, Sandeep S.; Zhang, Tony J.; McDonald, Rachel; Al Rashida, Vanessa; Kondapalli, Nitin; Barger, Philip; Ludbrook, Philip; Cedars, Ari M.

In: Baylor University Medical Center Proceedings, Vol. 31, No. 1, 01.01.2018, p. 12-19.

Research output: Contribution to journalArticle

Sodhi, Sandeep S. ; Zhang, Tony J. ; McDonald, Rachel ; Al Rashida, Vanessa ; Kondapalli, Nitin ; Barger, Philip ; Ludbrook, Philip ; Cedars, Ari M. / Effects of eplerenone on markers of myocardial fibrosis, 6-minute walk distance, and quality of life in adults with tetralogy of fallot and complete transposition of the great arteries. In: Baylor University Medical Center Proceedings. 2018 ; Vol. 31, No. 1. pp. 12-19.
@article{60d9d24c51874b32b674cae2a292fd0f,
title = "Effects of eplerenone on markers of myocardial fibrosis, 6-minute walk distance, and quality of life in adults with tetralogy of fallot and complete transposition of the great arteries",
abstract = "Ventricular dysfunction is common among patients with repaired cyanotic congenital heart disease. To date, no pharmacologic intervention has been demonstrated to be beneficial in this setting. To begin addressing this knowledge gap, we conducted a single-center prospective, randomized, open-label pilot study to investigate the effects of eplerenone on serologic markers of collagen turnover and inflammation, 6-minute walk distance, and quality of life in patients with tetralogy of Fallot (TOF) or transposition of the great arteries with a systemic right ventricle (transposition of the great arteries [TGA]). Patients were randomized to a 3-month drug-free period at the beginning of the treatment period or at the end. All patients received 12 months of eplerenone therapy during the treatment period. Twenty-six patients were enrolled in the trial; 17 completed the study protocol: 8 with TOF and 9 with TGV. Eplerenone had no effect on serum levels of procollagen 1 N-terminal peptide (PINP), procollagen 3 N-terminal peptide (PIIINP), or galectin-3 (G3). Similarly, eplerenone had no effect on 6-minute walk distance or quality of life. In conclusion, PINP and PIIINP levels are as high as or higher in patients with TOF and TGA than in patients with normal cardiac anatomy and heart failure, whereas G3 levels are lower. Eplerenone is well tolerated by adults born with congenital heart disease.",
keywords = "Adult congenital heart disease, Eplerenone, Tetralogy of Fallot, Transposition of the great vessels",
author = "Sodhi, {Sandeep S.} and Zhang, {Tony J.} and Rachel McDonald and {Al Rashida}, Vanessa and Nitin Kondapalli and Philip Barger and Philip Ludbrook and Cedars, {Ari M.}",
year = "2018",
month = "1",
day = "1",
doi = "10.1080/08998280.2017.1396176",
language = "English (US)",
volume = "31",
pages = "12--19",
journal = "Baylor University Medical Center Proceedings",
issn = "0899-8280",
publisher = "Taylor and Francis Ltd.",
number = "1",

}

TY - JOUR

T1 - Effects of eplerenone on markers of myocardial fibrosis, 6-minute walk distance, and quality of life in adults with tetralogy of fallot and complete transposition of the great arteries

AU - Sodhi, Sandeep S.

AU - Zhang, Tony J.

AU - McDonald, Rachel

AU - Al Rashida, Vanessa

AU - Kondapalli, Nitin

AU - Barger, Philip

AU - Ludbrook, Philip

AU - Cedars, Ari M.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Ventricular dysfunction is common among patients with repaired cyanotic congenital heart disease. To date, no pharmacologic intervention has been demonstrated to be beneficial in this setting. To begin addressing this knowledge gap, we conducted a single-center prospective, randomized, open-label pilot study to investigate the effects of eplerenone on serologic markers of collagen turnover and inflammation, 6-minute walk distance, and quality of life in patients with tetralogy of Fallot (TOF) or transposition of the great arteries with a systemic right ventricle (transposition of the great arteries [TGA]). Patients were randomized to a 3-month drug-free period at the beginning of the treatment period or at the end. All patients received 12 months of eplerenone therapy during the treatment period. Twenty-six patients were enrolled in the trial; 17 completed the study protocol: 8 with TOF and 9 with TGV. Eplerenone had no effect on serum levels of procollagen 1 N-terminal peptide (PINP), procollagen 3 N-terminal peptide (PIIINP), or galectin-3 (G3). Similarly, eplerenone had no effect on 6-minute walk distance or quality of life. In conclusion, PINP and PIIINP levels are as high as or higher in patients with TOF and TGA than in patients with normal cardiac anatomy and heart failure, whereas G3 levels are lower. Eplerenone is well tolerated by adults born with congenital heart disease.

AB - Ventricular dysfunction is common among patients with repaired cyanotic congenital heart disease. To date, no pharmacologic intervention has been demonstrated to be beneficial in this setting. To begin addressing this knowledge gap, we conducted a single-center prospective, randomized, open-label pilot study to investigate the effects of eplerenone on serologic markers of collagen turnover and inflammation, 6-minute walk distance, and quality of life in patients with tetralogy of Fallot (TOF) or transposition of the great arteries with a systemic right ventricle (transposition of the great arteries [TGA]). Patients were randomized to a 3-month drug-free period at the beginning of the treatment period or at the end. All patients received 12 months of eplerenone therapy during the treatment period. Twenty-six patients were enrolled in the trial; 17 completed the study protocol: 8 with TOF and 9 with TGV. Eplerenone had no effect on serum levels of procollagen 1 N-terminal peptide (PINP), procollagen 3 N-terminal peptide (PIIINP), or galectin-3 (G3). Similarly, eplerenone had no effect on 6-minute walk distance or quality of life. In conclusion, PINP and PIIINP levels are as high as or higher in patients with TOF and TGA than in patients with normal cardiac anatomy and heart failure, whereas G3 levels are lower. Eplerenone is well tolerated by adults born with congenital heart disease.

KW - Adult congenital heart disease

KW - Eplerenone

KW - Tetralogy of Fallot

KW - Transposition of the great vessels

UR - http://www.scopus.com/inward/record.url?scp=85045127209&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85045127209&partnerID=8YFLogxK

U2 - 10.1080/08998280.2017.1396176

DO - 10.1080/08998280.2017.1396176

M3 - Article

C2 - 29686545

AN - SCOPUS:85045127209

VL - 31

SP - 12

EP - 19

JO - Baylor University Medical Center Proceedings

JF - Baylor University Medical Center Proceedings

SN - 0899-8280

IS - 1

ER -